Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.04-0.22 (-0.52%)
At close: 04:00PM EDT
42.04 0.00 (0.00%)
After hours: 06:20PM EDT
Advertisement
Sign in to post a message.
  • A
    Anita
    What's behind the big rise today?
  • J
    Joe
    Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture which I believe is a dilution of the balance sheet. At these times this is not a prudent move.
  • S
    Shiekh
    Thanks, I'll check them out.Thanks for the tip!Thanks for the update!
  • J
    Janet
    Has the FDA approved this test? Has the test been accepted by any insurance networks?
  • S
    Steven
    When does the ECLIPSE test report out?
  • F
    Frank
    It seems investors lost interests in GH
  • J
    Jeffrey
    Massively undervalued. $3bn market cap with $1.6bn cash. Revenues of $460m-$470m expected this year. Clinical volumes up 47%. Shield LDT now launched.
  • E
    End2War
    This stock has suffered a sharp PPS decline to a level that it now looks to be a very good bargain basement play. It has great technology and an enormous TAM, and the EPIC deal is going to speed it's sales growth significantly, as it expands its product offerings. It is the clear leader in "liquid biopsy" and the many ways this technology can be used is quite promising for huge profits over time as sales growth is set to explode, IMO. Please don't listen to the short sellers that have latched onto this stock as it suffered a price decline in a difficult market environment. If you buy and hold till the market swings into a more positive mood, it will be recognized for the growth and profit potential that it has. Test results coming by the end of the year should help PPS from here. With its current $3 B MC and strong sales growth, it should be expected to provide a great investment for those that buy and patiently hold. GLTY and please do your own research and DD and never base your decisions on posters.
  • B
    Benjo
    This is going to be $3-4 !!
  • F
    Frank
    Sell a big loss. Just hold onto it
    Hope one day it may go up again
    Neutral
  • S
    Steven
    If the ECLIPSE test doesn’t produce outstanding results, this stock is DOA
  • e
    egghead
    I am not understanding what Doctor would prescribe a test that is not FDA approved? Am I missing something?
  • F
    Francis
    Ask the noticeably absent @Pauline how this cash printing machine is doing? Certainly not making any cash. Time to revise that target price down closer to $55. Even that would be a stretch.
  • F
    Francis
    A little rise, a bigger fall. A little less rise, a bigger fall. After 6 months that story is getting old. And to think they are in the market for your health. Right….
  • K
    Kalvin
    worse investment ever
  • F
    Francis
    Hahaha, off 33% in May and trying to outdo itself in June.
  • J
    Joe
    On the other hand profitability for testing isn't easy :
    Illumina (NASDAQ:ILMN) saw its Q1 2022 net income decline ~41% compared to the prior-year period due to a significant operating loss from its GRAIL division, which was acquired in August 2021.
  • O
    Oldguy794
    EXAS tried marketing a non approved early version of a stool CRC screening test called PreGenPlus in 2007. FDA was not pleased and sent EXAS a letter saying they believed regulatory approval was required for their device. Market responded as you would expect and the stock was punished.
  • F
    Francis
    It’s a long way reach that $123 target price. Can’t see that happening, regardless of valuation, underselling, overselling, or anything else.
  • J
    Joe
    Huge mistake from being swept up from the noble goal of predictive diagnostics, while ignoring the company's performance.
    The question now is to hold and hope for a buyout, or sell into the bounce.
    Unless the find a way to become profitable, the euphoria of last year is gone.
Advertisement
Advertisement